Strategies for nonviral nanoparticle‐based delivery of CRISPR/Cas9 therapeutics

A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity

Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116 · see citing works

Multiplex Genome Engineering Using CRISPR/Cas Systems

Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339 · see citing works

Genome engineering using the CRISPR-Cas9 system

Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133 · see citing works

RNA-Guided Human Genome Engineering via Cas9

Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210 · see citing works

The new frontier of genome engineering with CRISPR-Cas9

Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062 · see citing works

A Toll-like receptor recognizes bacterial DNA

Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491 · see citing works

CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes

Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., Romero, D. A., & Horvath, P. (2007) · Science · doi:10.1126/science.1138140 · Cited by 6,304 · see citing works

Development and Applications of CRISPR-Cas9 for Genome Engineering

Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762 · see citing works

Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression

Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S., Arkin, A. P., & Lim, W. A. (2013) · Cell · doi:10.1016/j.cell.2013.02.022 · Cited by 5,016 · see citing works

Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure.

Felgner, P. L., Gadek, T. R., Holm, M., Roman, R., Chan, H. W., Wenz, M., Northrop, J. P., RINGOLD, G. M., & Danielsen, M. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7413 · Cited by 4,954 · see citing works

DNA targeting specificity of RNA-guided Cas9 nucleases

Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741 · see citing works

Factors affecting the clearance and biodistribution of polymeric nanoparticles

Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699 · see citing works

CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes

Gilbert, L. A., Larson, M. H., Morsut, L., Liu, Z., Brar, G. A., Torres, S. E., Stern-Ginossar, N., Brandman, O., Whitehead, E. H., Doudna, J. A., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.044 · Cited by 3,696 · see citing works

Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives

Knop, K., Hoogenboom, R., Fischer, D., & Schubert, U. S. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200902672 · Cited by 3,533 · see citing works

Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity

Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299 · see citing works

Non-viral vectors for gene-based therapy

Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123 · see citing works

Knocking down barriers: advances in siRNA delivery

Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115 · see citing works

Small CRISPR RNAs Guide Antiviral Defense in Prokaryotes

Brouns, S. J. J., Jore, M. M., Lundgren, M., Westra, E. R., Slijkhuis, R. J. H., Snijders, A. P., Dickman, M. J., Makarova, K. S., Koonin, E. V., & John van der, O. O. S. T. (2008) · Science · doi:10.1126/science.1159689 · Cited by 2,593 · see citing works

Design and development of polymers for gene delivery

Pack, D. W., Hoffman, A. S., Pun, S., & Stayton, P. S. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1775 · Cited by 2,568 · see citing works

Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size

Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., Terada, Y., Kano, M. R., Miyazono, K., Uesaka, M., et al. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.166 · Cited by 2,429 · see citing works

Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product

Ishino, Y., Shinagawa, H., Makino, K., Amemura, M., & Nakata, A. (1987) · Journal of Bacteriology · doi:10.1128/jb.169.12.5429-5433.1987 · Cited by 2,421 · see citing works

Nonviral vectors for gene delivery

Mintzer, M. A., & Simanek, E. E. (2009) · Chemical Reviews · doi:10.1021/cr800409e · Cited by 2,366 · see citing works

CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering

Mali, P., Aach, J., Stranges, P. B., Esvelt, K. M., Moosburner, M., Kosuri, S., Yang, L., & Church, G. M. (2013) · Nature Biotechnology · doi:10.1038/nbt.2675 · Cited by 1,752 · see citing works

One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering

Yang, H., Wang, H., Shivalila, C. S., Cheng, A. W., Shi, L., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.08.022 · Cited by 1,596 · see citing works

Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo

Zuris, J. A., Thompson, D. B., Shu, Y., Guilinger, J. P., Bessen, J. L., Hu, J. H., Maeder, M. L., Joung, J. K., Chen, Z.-Y., & Liu, D. R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3081 · Cited by 1,460 · see citing works

Functional Repair of CFTR by CRISPR/Cas9 in Intestinal Stem Cell Organoids of Cystic Fibrosis Patients

Schwank, G., Koo, B.-K., Sasselli, V., Dekkers, J. F., Heo, I., Demircan, T., Sasaki, N., Boymans, S., Cuppen, E., van der Ent, C. K., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2013.11.002 · Cited by 1,424 · see citing works

Therapeutic genome editing: prospects and challenges

Cox, D. B. T., Platt, R. J., & Zhang, F. (2015) · Nature Medicine · doi:10.1038/nm.3793 · Cited by 1,336 · see citing works

Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells

Chu, V. T., Weber, T., Wefers, B., Wurst, W., Sander, S., Rajewsky, K., & Kühn, R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3198 · Cited by 1,210 · see citing works

Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery

Lin, S., Staahl, B. T., Alla, R. K., & Doudna, J. A. (2014) · eLife · doi:10.7554/elife.04766 · Cited by 1,189 · see citing works

Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system

Bikard, D., Jiang, W., Samai, P., Hochschild, A., Zhang, F., & Marraffini, L. A. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt520 · Cited by 1,111 · see citing works

In vivo gene editing in dystrophic mouse muscle and muscle stem cells

Tabebordbar, M., Zhu, K., Cheng, J. K. W., Chew, W. L., Widrick, J. J., Yan, W. X., Maesner, C., Wu, E. Y., Xiao, R., Ran, F. A., et al. (2016) · Science · doi:10.1126/science.aad5177 · Cited by 1,046 · see citing works

Minimal "Self" Peptides That Inhibit Phagocytic Clearance and Enhance Delivery of Nanoparticles

Rodriguez, P. L., Harada, T., Christian, D. A., Pantano, D. A., Tsai, R. K., & Discher, D. E. (2013) · Science · doi:10.1126/science.1229568 · Cited by 986 · see citing works

Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype

Yin, H., Xue, W., Chen, S., Bogorad, R. L., Benedetti, E., Grompe, M., Koteliansky, V., Sharp, P. A., Jacks, T., & Anderson, D. G. (2014) · Nature Biotechnology · doi:10.1038/nbt.2884 · Cited by 951 · see citing works

Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy

Long, C., Amoasii, L., Mireault, A. A., McAnally, J., Li, H. Z., Sanchez‐Ortiz, E., Bhattacharyya, S., Shelton, J. M., Bassel‐Duby, R., & Olson, E. N. (2015) · Science · doi:10.1126/science.aad5725 · Cited by 941 · see citing works

Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds

Zalatan, J. G., Lee, M. E., Almeida, R., Gilbert, L. A., Whitehead, E. H., La Russa, M., Tsai, J. C., Weissman, J. S., Dueber, J. E., Qi, L. S., et al. (2015) · Cell · doi:10.1016/j.cell.2014.11.052 · Cited by 938 · see citing works

A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing

Finn, J. D., Smith, A. R., Patel, M. C., Shaw, L., Youniss, M. R., van Heteren, J., Dirstine, T., Ciullo, C., Lescarbeau, R., Seitzer, J., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.014 · Cited by 878 · see citing works

Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo

Yin, H., Song, C.-Q., Dorkin, J. R., Zhu, L. J., Li, Y., Wu, Q., Park, A., Yang, J., Suresh, S., Bizhanova, A., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3471 · Cited by 876 · see citing works

CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells

Dever, D. P., Bak, R. O., Reinisch, A., Camarena, J., Washington, G., Nicolas, C. E., Pavel-Dinu, M., Saxena, N., Wilkens, A. B., Mantri, S., et al. (2016) · Nature · doi:10.1038/nature20134 · Cited by 864 · see citing works

Non Viral Vectors in Gene Therapy- An Overview

Ramamoorth, M. (2015) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2015/10443.5394 · Cited by 762 · see citing works

A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia

Tzelepis, K., Koike-Yusa, H., De Braekeleer, E., Li, Y., Metzakopian, E., Dovey, O. M., Mupo, A., Grinkevich, V., Li, M., Mazan, M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.079 · Cited by 761 · see citing works

Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair

Lee, K., Conboy, M., Park, H. M., Jiang, F., Kim, H. J., Dewitt, M. A., Mackley, V. A., Chang, K., Rao, A., Skinner, C., et al. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0137-2 · Cited by 755 · see citing works

Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses

Bertram, L., & Tanzi, R. E. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2494 · Cited by 747 · see citing works

Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection

Liang, X., Potter, J., Kumar, S., Zou, Y., Quintanilla, R., Sridharan, M., Carte, J., Chen, W., Roark, N., Ranganathan, S., et al. (2015) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2015.04.024 · Cited by 733 · see citing works

Generation of knock-in primary human T cells using Cas9 ribonucleoproteins

Schumann, K., Lin, S., Boyer, E., Simeonov, D. R., Subramaniam, M., Gate, R. E., Haliburton, G. E., Ye, C. J., Bluestone, J. A., Doudna, J. A., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1512503112 · Cited by 702 · see citing works

Exploring the Genomes of Cancer Cells: Progress and Promise

Stratton, M. R. (2011) · Science · doi:10.1126/science.1204040 · Cited by 688 · see citing works

State-of-the-art gene-based therapies: the road ahead

Kay, M. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2971 · Cited by 672 · see citing works

Advances in the delivery of RNA therapeutics: from concept to clinical reality

Kaczmarek, J. C., Kowalski, P. S., & Anderson, D. G. (2017) · Genome Medicine · doi:10.1186/s13073-017-0450-0 · Cited by 656 · see citing works

Self‐assembled DNA nanoclews for the efficient delivery of CRISPR–Cas9 for genome editing

Sun, W., Ji, W., Hall, J. M., Hu, Q., Wang, C., Beisel, C. L., & Gu, Z. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201506030 · Cited by 629 · see citing works

Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles

Wang, M., Zuris, J. A., Meng, F., Rees, H., Sun, S., Deng, P., Han, Y., Gao, X., Pouli, D., Wu, Q., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520244113 · Cited by 624 · see citing works

Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications

Liu, C., Zhang, L., Liu, H., & Cheng, K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.012 · Cited by 607 · see citing works

Direct cytosolic delivery of CRISPR/Cas9-ribonucleoprotein for efficient gene editing

Mout, R., Ray, M., Yesilbag Tonga, G., Lee, Y.-W., Tay, T., Sasaki, K., & Rotello, V. M. (2017) · ACS Nano · doi:10.1021/acsnano.6b07600 · Cited by 579 · see citing works

Strategies for extended serum half-life of protein therapeutics

Kontermann, R. E. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.06.012 · Cited by 576 · see citing works

Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus

Ebina, H., Misawa, N., Kanemura, Y., & Koyanagi, Y. (2013) · Scientific Reports · doi:10.1038/srep02510 · Cited by 565 · see citing works

Targeting of nanoparticles to the clathrin-mediated endocytic pathway

Harush-Frenkel, O., Debotton, N., Benita, S., & Altschuler, Y. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.11.135 · Cited by 564 · see citing works

CRISPR/Cas9-based genome editing for disease modeling and therapy: challenges and opportunities for nonviral delivery

Wang, H.-X., Li, M., Lee, C. M., Chakraborty, S., Kim, H.-W., Bao, G., & Leong, K. W. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00799 · Cited by 560 · see citing works

Non‐Viral CRISPR/Cas Gene Editing In Vitro and In Vivo Enabled by Synthetic Nanoparticle Co‐Delivery of Cas9 mRNA and sgRNA

Miller, J. B., Zhang, S., Kos, P., Xiong, H., Zhou, K., Perelman, S. S., Zhu, H., & Siegwart, D. J. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201610209 · Cited by 540 · see citing works

Polyethylenimine-graft-Poly(ethylene glycol) Copolymers: Influence of Copolymer Block Structure on DNA Complexation and Biological Activities as Gene Delivery System

Petersen, H., Fechner, P. M., Martin, A. L., Kunath, K., Stolnik, S., Roberts, C. J., Fischer, D., Davies, M. C., & Kissel, T. (2002) · Bioconjugate Chemistry · doi:10.1021/bc025529v · Cited by 534 · see citing works

Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing

Yin, H., Song, C.-Q., Suresh, S., Wu, Q., Walsh, S., Rhym, L. H., Mintzer, E., Bolukbasi, M. F., Zhu, L. J., Kauffman, K., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.4005 · Cited by 499 · see citing works

Editing the epigenome: technologies for programmable transcription and epigenetic modulation

Thakore, P. I., Black, J. B., Hilton, I. B., & Gersbach, C. A. (2016) · Nature Methods · doi:10.1038/nmeth.3733 · Cited by 451 · see citing works

Thermo-triggered release of CRISPR-Cas9 system by lipid-encapsulated gold nanoparticles for tumor therapy

Wang, P., Zhang, L., Zheng, W., Cong, L., Guo, Z., Xie, Y., Wang, L., Tang, R., Feng, Q., Hamada, Y., et al. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201708689 · Cited by 410 · see citing works

A boronic acid–rich dendrimer with robust and unprecedented efficiency for cytosolic protein delivery and CRISPR-Cas9 gene editing

Liu, C., Wan, T. Y., Wang, H., Zhang, S., Yuan, P., & Cheng, Y. (2019) · Science Advances · doi:10.1126/sciadv.aaw8922 · Cited by 398 · see citing works

Nanoparticle delivery of CRISPR into the brain rescues a mouse model of fragile X syndrome from exaggerated repetitive behaviours

Lee, B., Lee, K., Panda, S., Gonzales-Rojas, R., Chong, A., Bugay, V., Park, H. M., Brenner, R., Murthy, N., & Lee, H. Y. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0252-8 · Cited by 361 · see citing works

Dynamic changes in the characteristics of cationic lipidic vectors after exposure to mouse serum: implications for intravenous lipofection

Li, S., Tseng, W.-C., Stolz, D. B., Wu, S.-Y., Watkins, S. C., & Huang, L. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300865 · Cited by 351 · see citing works

Engineering the delivery system for CRISPR-based genome editing

Glass, Z., Lee, M., Li, Y., & Xu, Q. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2017.11.006 · Cited by 345 · see citing works

Polymer–Lipid Nanoparticles for Systemic Delivery of mRNA to the Lungs

Kaczmarek, J. C., Patel, A. K., Kauffman, K. J., Fenton, O. S., Webber, M. J., Heartlein, M. W., DeRosa, F., & Anderson, D. G. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201608450 · Cited by 337 · see citing works

Cancer-Associated Protein Kinase C Mutations Reveal Kinase’s Role as Tumor Suppressor

Antal, C. E., Hudson, A., Kang, E., Zanca, C., Wirth, C., Stephenson, N. L., Trotter, E. W., Gallegos, L. L., Miller, C. J., Furnari, F. B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.001 · Cited by 331 · see citing works

CRISPR–Cas systems: beyond adaptive immunity

Westra, E. R., Buckling, A., & Fineran, P. C. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3241 · Cited by 322 · see citing works

Targeted Delivery of CRISPR/Cas9‐Mediated Cancer Gene Therapy via Liposome‐Templated Hydrogel Nanoparticles

Chen, Z., Liu, F., Chen, Y., Liu, J., Wang, X., Chen, A. T., Deng, G., Zhang, H., Liu, J., Hong, Z., et al. (2017) · Advanced Functional Materials · doi:10.1002/adfm.201703036 · Cited by 297 · see citing works

A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo

Jiang, C., Mei, M., Li, B., Zhu, X., Zu, W., Tian, Y., Wang, Q., Guo, Y., Dong, Y., & Tan, X. (2017) · Cell Research · doi:10.1038/cr.2017.16 · Cited by 295 · see citing works

Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling

Zuckermann, M., Hovestadt, V., Knobbe-Thomsen, C. B., Zapatka, M., Northcott, P. A., Schramm, K., Belic, J., Jones, D., Tschida, B. R., Moriarity, B. S., et al. (2015) · Nature Communications · doi:10.1038/ncomms8391 · Cited by 294 · see citing works

CRISPR/Cas9‐mediated genome engineering: An adeno‐associated viral (AAV) vector toolbox

Senís, E., Fatouros, C., Große, S., Wiedtke, E., Niopek, D., Mueller, A., Börner, K., & Grimm, D. (2014) · Biotechnology Journal · doi:10.1002/biot.201400046 · Cited by 262 · see citing works

Cas9-mediated targeting of viral RNA in eukaryotic cells

Price, A. A., Sampson, T. R., Ratner, H. K., Grakoui, A., & Weiss, D. S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1422340112 · Cited by 252 · see citing works

In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges

Mout, R., Ray, M., Lee, Y.-W., Scaletti, F., & Rotello, V. M. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00057 · Cited by 247 · see citing works

Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication

Dong, C., Qu, L., Wang, H., Wei, L., Dong, Y., & Xiong, S. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.03.015 · Cited by 245 · see citing works

Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus

Zhen, S. M., Hua, L., Liu, Y.-H., Gao, L.-C., Fu, J., Wan, D.-Y., Dong, L.-H., Song, H.-F., & Gao, X. (2015) · Gene Therapy · doi:10.1038/gt.2015.2 · Cited by 233 · see citing works

Synthesizing AND gate genetic circuits based on CRISPR-Cas9 for identification of bladder cancer cells

Liu, Y., Zeng, Y., Liu, L., Zhuang, C., Fu, X., Huang, W., & Cai, Z. (2014) · Nature Communications · doi:10.1038/ncomms6393 · Cited by 223 · see citing works

Nonviral Genome Editing Based on a Polymer-Derivatized CRISPR Nanocomplex for Targeting Bacterial Pathogens and Antibiotic Resistance

Kang, Y. K., Kwon, K., Ryu, J. S., Lee, H. N., Park, C., & Chung, H. J. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00676 · Cited by 210 · see citing works

Cationic liposomal lipids: From gene carriers to cell signaling

Lonez, C., Vandenbranden, M., & Ruysschaert, J. (2008) · Progress in Lipid Research · doi:10.1016/j.plipres.2008.03.002 · Cited by 208 · see citing works

Challenges in CRISPR/CAS9 delivery: potential roles of nonviral vectors

Li, L., He, Z.-Y., Wei, X.-W., Gao, G.-P., & Wei, Y.-Q. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.069 · Cited by 202 · see citing works

A CRISPR/Cas9-Based System for Reprogramming Cell Lineage Specification

Chakraborty, S., Ji, H., Kabadi, A. M., Gersbach, C. A., Christoforou, N., & Leong, K. W. (2014) · Stem Cell Reports · doi:10.1016/j.stemcr.2014.09.013 · Cited by 197 · see citing works

Delivery and Specificity of CRISPR/Cas9 Genome Editing Technologies for Human Gene Therapy

Gori, J. L., Hsu, P. D., Maeder, M. L., Shen, S., Welstead, G. G., & Bumcrot, D. A. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.074 · Cited by 192 · see citing works

Nanocarrier-Mediated Chemo-Immunotherapy Arrested Cancer Progression and Induced Tumor Dormancy in Desmoplastic Melanoma

Liu, Q., Chen, F., Hou, L., Shen, L., Zhang, X., Wang, D., & Huang, L. (2018) · ACS Nano · doi:10.1021/acsnano.8b01890 · Cited by 182 · see citing works

Genetics and genomics of Parkinson’s disease

Lin, M. K., & Farrer, M. J. (2014) · Genome Medicine · doi:10.1186/gm566 · Cited by 179 · see citing works

Reduced Blood Lipid Levels With In Vivo CRISPR-Cas9 Base Editing of ANGPTL3

Chadwick, A. C., Evitt, N. H., Lv, W., & Musunuru, K. (2018) · Circulation · doi:10.1161/circulationaha.117.031335 · Cited by 163 · see citing works

Chinese scientists to pioneer first human CRISPR trial

Cyranoski, D. (2016) · Nature · doi:10.1038/nature.2016.20302 · Cited by 160 · see citing works

Lipid nanoparticles for short interfering RNA delivery

Leung, A. K. K., Tam, Y. Y. C., & Cullis, P. R. (2014) · Advances in genetics · doi:10.1016/b978-0-12-800148-6.00004-3 · Cited by 158 · see citing works

Engineered Viruses as Genome Editing Devices

Chen, X., & Gonçalves, M. A. F. V. (2015) · Molecular Therapy · doi:10.1038/mt.2015.164 · Cited by 151 · see citing works

Expressing Transgenes That Exceed the Packaging Capacity of Adeno-Associated Virus Capsids

Chamberlain, K., Riyad, J. M., & Weber, T. (2016) · Human Gene Therapy Methods · doi:10.1089/hgtb.2015.140 · Cited by 141 · see citing works

Targeted drug delivery to melanoma

Liu, Q., Das, M., Liu, Y., & Huang, L. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.09.016 · Cited by 138 · see citing works

Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Therapeutics

Givens, B. E., Naguib, Y. W., Geary, S. M., Devor, E. J., & Salem, A. K. (2018) · The AAPS Journal · doi:10.1208/s12248-018-0267-9 · Cited by 132 · see citing works

Targeted delivery of CRISPR/Cas9 to prostate cancer by modified gRNA using a flexible aptamer-cationic liposome

Zhen, S., Takahashi, Y., Narita, S., Yang, Y., & Xu, L. (2016) · Oncotarget · doi:10.18632/oncotarget.14072 · Cited by 125 · see citing works

Polymer- and lipid-based nanoparticle therapeutics for the treatment of liver diseases

Li, L., Wang, H., Ong, Z. Y., Xu, K., Ee, P. L. R., Zheng, S., Hedrick, J. L., & Yang, Y. Y. (2010) · Nano Today · doi:10.1016/j.nantod.2010.06.007 · Cited by 116 · see citing works

The role of dioleoylphosphatidylethanolamine (DOPE) in targeted gene delivery with mannosylated cationic liposomes via intravenous route

Hattori, Y., Suzuki, S., Kawakami, S., Yamashita, F., & Hashida, M. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.08.012 · Cited by 110 · see citing works

Systemic delivery of CRISPR/Cas9 with PEG-PLGA nanoparticles for chronic myeloid leukemia targeted therapy

Liu, Y., Zhao, G., Xu, C., Luo, Y., Lu, Z.-D., & Wang, J. (2018) · Biomaterials Science · doi:10.1039/c8bm00263k · Cited by 110 · see citing works

Cationic Polymer‐Mediated CRISPR/Cas9 Plasmid Delivery for Genome Editing

Zhang, Z., Wan, T. Y., Chen, Y., Chen, Y., Sun, H., Cao, T., Songyang, Z., Tang, G., Wu, C., Yuan, P., et al. (2018) · Macromolecular Rapid Communications · doi:10.1002/marc.201800068 · Cited by 108 · see citing works

Polymeric nanocarriers for non-viral gene delivery

Li, L., Wei, Y., & Gong, C. (2015) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2015.2069 · Cited by 106 · see citing works

Cholesterol-Dependent Macropinocytosis and Endosomal Escape Control the Transfection Efficiency of Lipoplexes in CHO Living Cells

Cardarelli, F., Pozzi, D., Bifone, A., Marchini, C., & Caracciolo, G. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200374e · Cited by 104 · see citing works

Effective PEI-mediated delivery of CRISPR-Cas9 complex for targeted gene therapy

Ryu, N., Kim, M.-A., Park, D., Lee, B., Kim, Y., Kim, K., Baek, J., Kim, W. J., Lee, K.-Y., & Kim, U. (2018) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2018.06.009 · Cited by 95 · see citing works

Tumor immune microenvironment and nano-immunotherapeutics in colorectal cancer

Xiong, Y., Wang, Y., & Tiruthani, K. (2019) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2019.102034 · Cited by 88 · see citing works

CRISPR genome engineering and viral gene delivery: A case of mutual attraction

Schmidt, F., & Grimm, D. (2015) · Biotechnology Journal · doi:10.1002/biot.201400529 · Cited by 83 · see citing works

Nanoparticle-Mediated Trapping of Wnt Family Member 5A in Tumor Microenvironments Enhances Immunotherapy for B-Raf Proto-Oncogene Mutant Melanoma

Liu, Q., Zhu, H., Tiruthani, K., Shen, L., Chen, F., Gao, K., Zhang, X., Hou, L., Wang, D., Liu, R., et al. (2018) · ACS Nano · doi:10.1021/acsnano.7b07384 · Cited by 83 · see citing works

Tumor pH e -triggered charge-reversal and redox-responsive nanoparticles for docetaxel delivery in hepatocellular carcinoma treatment

Chen, F., Zhang, J., Wang, L., Wang, Y., & Chen, M. (2015) · Nanoscale · doi:10.1039/c5nr04612b · Cited by 81 · see citing works

PEGylated Chitosan for Nonviral Aerosol and Mucosal Delivery of the CRISPR/Cas9 System in Vitro

Zhang, H., Bahamondez‐Canas, T., Zhang, Y., Leal, J., & Smyth, H. D. C. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00434 · Cited by 81 · see citing works

Cytosolic delivery of CRISPR/Cas9 ribonucleoproteins for genome editing using chitosan-coated red fluorescent protein

Qiao, J., Sun, W., Lin, S., Jin, R., Ma, L., & Liu, Y. (2019) · Chemical Communications · doi:10.1039/c9cc00010k · Cited by 79 · see citing works

Nucleolin targeting AS1411 aptamer modified pH-sensitive micelles for enhanced delivery and antitumor efficacy of paclitaxel

Zhang, J., Chen, R., Fang, X., Chen, F., Wang, Y., & Chen, M. (2015) · Nano Research · doi:10.1007/s12274-014-0619-4 · Cited by 78 · see citing works

Glycyrrhetinic acid-decorated and reduction-sensitive micelles to enhance the bioavailability and anti-hepatocellular carcinoma efficacy of tanshinone IIA

Chen, F., Zhang, J., He, Y., Fang, X., Wang, Y., & Chen, M. (2015) · Biomaterials Science · doi:10.1039/c5bm00224a · Cited by 73 · see citing works

Nanoparticles for CRISPR–Cas9 delivery

Glass, Z., Li, Y., & Xu, Q. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0158-x · Cited by 69 · see citing works

Combinatorial Library Strategies for Synthesis of Cationic Lipid-Like Nanoparticles and their Potential Medical Applications

Altınoglu, S., Wang, M., & Xu, Q. (2015) · Nanomedicine · doi:10.2217/nnm.14.192 · Cited by 68 · see citing works

BRAF peptide vaccine facilitates therapy of murine BRAF-mutant melanoma

Liu, Q., Zhu, H., Liu, Y., Musetti, S., & Huang, L. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2079-7 · Cited by 62 · see citing works

Chemical Biology Approaches to Genome Editing: Understanding, Controlling, and Delivering Programmable Nucleases

Hu, J. H., Davis, K. M., & Liu, D. R. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2015.12.009 · Cited by 58 · see citing works

Cytosolic and Nuclear Delivery of CRISPR/Cas9-ribonucleoprotein for Gene Editing Using Arginine Functionalized Gold Nanoparticles

Mout, R., & Rotello, V. M. (2017) · BIO-PROTOCOL · doi:10.21769/bioprotoc.2586 · Cited by 44 · see citing works

Preparation, characterization, and anticancer efficacy of evodiamine-loaded PLGA nanoparticles

Zou, L., Chen, F., Bao, J., Wang, S., Wang, L., Chen, M., He, C., & Wang, Y. (2014) · Drug Delivery · doi:10.3109/10717544.2014.920936 · Cited by 41 · see citing works

Intracellular delivery of the PTEN protein using cationic lipidoids for cancer therapy

Altınoglu, S., Wang, M., Li, K. Q., Li, Y., & Xu, Q. (2016) · Biomaterials Science · doi:10.1039/c6bm00580b · Cited by 39 · see citing works

Live Visualization of HIV-1 Proviral DNA Using a Dual-Color-Labeled CRISPR System

Ma, Y., Wang, M., Li, W., Zhang, Z., Zhang, X., Wu, G., Tan, T., Cui, Z., & Zhang, X. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.7b03584 · Cited by 39 · see citing works

CRISPR-based DNA and RNA detection with liquid-liquid phase separation

Spoelstra, W. K., Jacques, J. M., Gonzalez-Linares, R., Nóbrega, F. L., Haagsma, A. C., Dogterom, M., Meijer, D. H., Idema, T., Brouns, S. J. J., & Reese, L. (2021) · Biophysical Journal · doi:10.1016/j.bpj.2021.02.013 · Cited by 39 · see citing works

Reversal of paclitaxel resistance in human ovarian cancer cells with redox-responsive micelles consisting of α-tocopheryl succinate-based polyphosphoester copolymers

Chen, F., Zhang, J., Fang, X., Yu, H., Liu, Y., Li, H., Wang, Y., & Chen, M. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.150 · Cited by 36 · see citing works

Bile Acid−Oligopeptide Conjugates Interact with DNA and Facilitate Transfection

Kish, P. E., Tsume, Y., Kijek, P., Lanigan, T. M., Hilfinger, J. M., & Roessler, B. J. (2006) · Molecular Pharmaceutics · doi:10.1021/mp060025q · Cited by 32 · see citing works

Targeting Mutant KRAS for Anticancer Therapy

Chen, F., Alphonse, M. P., Liu, Y., & Liu, Q. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190902151307 · Cited by 15 · see citing works

Membrane Microdomain Structures of Liposomes and Their Contribution to the Cellular Uptake Efficiency into HeLa Cells

Onuki, Y., Obata, Y., Kawano, K., Sano, H., Matsumoto, R., Hayashi, Y., & Takayama, K. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00601 · Cited by 14 · see citing works

CRISPR-based DNA and RNA detection with liquid-liquid phase separationPreprint

Spoelstra, W. K., Jacques, J. M., Nóbrega, F. L., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/471482 · Cited by 11 · see citing works

Zinc-dependent Deacetylase (HDAC) Inhibitors with Different ZBG Groups

Li, Y., Wang, F., Chen, X., Wang, J., Zhao, Y., Li, Y., & He, B. (1969) · Current Topics in Medicinal Chemistry · Cited by 7 · see citing works

Using CRISPR/Cas9 to modify the genome of cattle

Lotti, S. N. (2017) · Illinois Digital Environment for Access to Learning and Scholarship (University of Illinois at Urbana-Champaign) · Cited by 2 · see citing works

Drug delivery systems for RNA therapeutics

Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349 · see citing works

CRISPR/Cas9 therapeutics: progress and prospects

Li, T., Yang, Y., Qi, H., Cui, W., Zhang, L., Fu, X., He, X., Liu, M., Li, P., & Yu, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01309-7 · Cited by 770 · see citing works

Past, present, and future of CRISPR genome editing technologies

Pacesa, M., Pelea, O., & Jinek, M. (2024) · Cell · doi:10.1016/j.cell.2024.01.042 · Cited by 609 · see citing works

CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors

Wang, D., Zhang, F., & Gao, G. (2020) · Cell · doi:10.1016/j.cell.2020.03.023 · Cited by 526 · see citing works

RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges

Yu, A., Choi, Y. H., & Tu, M. (2020) · Pharmacological Reviews · doi:10.1124/pr.120.019554 · Cited by 405 · see citing works

Nanoparticle Delivery of CRISPR/Cas9 for Genome Editing

Duan, L., Ouyang, K., Xu, X. G., Xu, L., Wen, C., Zhou, X., Qin, Z., Xu, Z., Sun, W., & Liang, Y. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.673286 · Cited by 400 · see citing works

DNA hydrogel-based gene editing and drug delivery systems

Mo, F., Jiang, K., Zhao, D. S., Wang, Y., Song, J., & Tan, W. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.018 · Cited by 306 · see citing works

Recent Advances in CRISPR/Cas9 Delivery Strategies

Yip, B. H. (2020) · Biomolecules · doi:10.3390/biom10060839 · Cited by 303 · see citing works

Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment

Xu, X., Liu, C., Wang, Y., Koivisto, O., Zhou, J., Shu, Y., & Zhang, H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113891 · Cited by 295 · see citing works

In vivo gene delivery mediated by non-viral vectors for cancer therapy

Mohammadinejad, R., Dehshahri, A., Madamsetty, V. S., Zahmatkeshan, M., Tavakol, S., Makvandi, P., Khorsandi, D., Pardakhty, A., Ashrafizadeh, M., Afshar, E. G., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.06.038 · Cited by 238 · see citing works

How can nanotechnology help to combat COVID-19? Opportunities and urgent need

Campos, E. V. R., Pereira, A. D. E. S., de Oliveira, J. L., Carvalho, L. B., Guilger‐Casagrande, M., de Lima, R., & Fraceto, L. F. (2020) · Journal of Nanobiotechnology · doi:10.1186/s12951-020-00685-4 · Cited by 228 · see citing works

CRISPR-Cas-Based Antimicrobials: Design, Challenges, and Bacterial Mechanisms of Resistance

Mayorga-Ramos, A., Zúñiga-Miranda, J., Carrera-Pacheco, S. E., Barba‐Ostria, C., & Guamán, L. P. (2023) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.2c00649 · Cited by 223 · see citing works

CRISPR-Cas Tools and Their Application in Genetic Engineering of Human Stem Cells and Organoids

Hendriks, D. F. G., Clevers, H. C., & Artegiani, B. (2020) · Cell stem cell · doi:10.1016/j.stem.2020.10.014 · Cited by 196 · see citing works

Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy

Rasul, M. F., Hussen, B. M., Salihi, A. B., Ismael, B. S., Jalal, P. J., Zanichelli, A., Jamali, E., Baniahmad, A., Ghafouri‐Fard, S., Basiri, A., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01487-4 · Cited by 180 · see citing works

CRISPR-Cas for genome editing: Classification, mechanism, designing and applications

Bhatia, S. K., ., P., & Yadav, S. K. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.124054 · Cited by 165 · see citing works

Principles of CRISPR-Cas9 technology: Advancements in genome editing and emerging trends in drug delivery

Aljabali, A. A. A., El‐Tanani, M., & Tambuwala, M. M. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105338 · Cited by 156 · see citing works

CRISPR/Cas: Advances, Limitations, and Applications for Precision Cancer Research

Yang, Y., Xu, J., Ge, S., & Lai, L. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.649896 · Cited by 160 · see citing works

Delivery of Tissue-Targeted Scalpels: Opportunities and Challenges for In Vivo CRISPR/Cas-Based Genome Editing

Wei, T., Cheng, Q., Farbiak, L., Anderson, D. G., Langer, R., & Siegwart, D. J. (2020) · ACS Nano · doi:10.1021/acsnano.0c04707 · Cited by 137 · see citing works

Nanocarrier-Mediated Delivery of miRNA, RNAi, and CRISPR-Cas for Plant Protection: Current Trends and Future Directions

Mujtaba, M., Wang, D., Carvalho, L. B., de Oliveira, J. L., Pereira, A. D. E. S., Sharif, R., Jogaiah, S., Paidi, M. K., Wang, L., Ali, Q., et al. (2021) · ACS Agricultural Science & Technology · doi:10.1021/acsagscitech.1c00146 · Cited by 133 · see citing works

CRISPR/Cas9 systems: Delivery technologies and biomedical applications

Du, Y., Liu, Y., Hu, J., Peng, X., & Liu, Z. (2023) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2023.100854 · Cited by 135 · see citing works

Solid lipid nanoparticles for targeted natural and synthetic drugs delivery in high-incidence cancers, and other diseases: Roles of preparation methods, lipid composition, transitional stability, and release profiles in nanocarriers’ development

Mohammed, H. A., Khan, R. A., Singh, V., Yusuf, M., Akhtar, N., Sulaiman, G. M., Albukhaty, S., Abdellatif, A. A. H., Khan, M., Mohammed, S. A. A., et al. (2023) · Nanotechnology Reviews · doi:10.1515/ntrev-2022-0517 · Cited by 124 · see citing works

Comparison of the Feasibility, Efficiency, and Safety of Genome Editing Technologies

Castro, N. G. G., Bjelic, J., Malhotra, G., Huang, C., & Alsaffar, S. H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910355 · Cited by 107 · see citing works

Novel Strategy to Combat Antibiotic Resistance: A Sight into the Combination of CRISPR/Cas9 and Nanoparticles

Wan, F., Draz, M. S., Gu, M., Yu, W., Ruan, Z., & Luo, Q. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030352 · Cited by 103 · see citing works

Targeting miRNA by CRISPR/Cas in cancer: advantages and challenges

Hussen, B. M., Rasul, M. F., Abdullah, S. R., Hidayat, H. J., Faraj, G. S. H., Ali, F. A., Salihi, A. B., Baniahmad, A., Ghafouri‐Fard, S., Rahman, M., et al. (2023) · Military Medical Research · doi:10.1186/s40779-023-00468-6 · Cited by 97 · see citing works

Recent advances in liposome formulations for breast cancer therapeutics

Yang, B., Song, B.-P., Shankar, S., Guller, A., & Deng, W. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03850-6 · Cited by 80 · see citing works

Advances in application of genome editing in tomato and recent development of genome editing technology

Xia, X., Cheng, X., Li, R., Yao, J., Li, Z., & Cheng, Y. (2021) · Theoretical and Applied Genetics · doi:10.1007/s00122-021-03874-3 · Cited by 78 · see citing works

Nanovaccines: An effective therapeutic approach for cancer therapy

Gurunathan, S., Pratheep, T., Wang, L., Cao, Q., & Kim, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115992 · Cited by 76 · see citing works

Gene Editing by Extracellular Vesicles

Kostyushev, D. S., Kostyusheva, A., Brezgin, S., Vv, S., Volchkova, E. V., Lukashev, A. N., & Chulanov, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197362 · Cited by 73 · see citing works

Comparative analysis of lipid Nanoparticle-Mediated delivery of CRISPR-Cas9 RNP versus mRNA/sgRNA for gene editing in vitro and in vivo

Walther, J., Porenta, D., Wilbie, D., Seinen, C. W., Benne, N., Yang, Q., de Jong, O. G., Lei, Z., & Mastrobattista, E. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114207 · Cited by 77 · see citing works

Advances in Nanoparticles as Non-Viral Vectors for Efficient Delivery of CRISPR/Cas9

Kim, M., Hwang, Y., Lim, S., Jang, H., & Kim, H. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16091197 · Cited by 75 · see citing works

Lipid nanoparticles: The game-changer in CRISPR-Cas9 genome editing

Farsani, A. M., Mokhtari, N., Nooraei, S., Bahrulolum, H., Akbari, A., Farsani, Z. M., Khatami, S., Ebadi, M. S., & Ahmadian, G. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24606 · Cited by 74 · see citing works

Nanocarriers: A novel strategy for the delivery of CRISPR/Cas systems

Hejabi, F., Abbaszadeh, M. S., Taji, S., O’Neill, A., Farjadian, F., & Doroudian, M. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.957572 · Cited by 69 · see citing works

Rapid design and development of CRISPR-Cas13a targeting SARS-CoV-2 spike protein

Wang, L., Zhou, J., Wang, Q., Wang, Y., & Kang, C. (2020) · Theranostics · doi:10.7150/thno.51479 · Cited by 62 · see citing works

A Simple and Quick Method for Loading Proteins in Extracellular Vesicles

Busatto, S., Iannotta, D., Walker, S. A., Marzio, L. D., & Wolfram, J. (2021) · Pharmaceuticals · doi:10.3390/ph14040356 · Cited by 63 · see citing works

Antibacterial and antiviral high-performance nanosystems to mitigate new SARS-CoV-2 variants of concern

Tiwari, S., Juneja, S., Ghosal, A., Bandara, N., Khan, R., Wallen, S. L., Ramakrishna, S., & Kaushik, A. K. (2021) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2021.100363 · Cited by 61 · see citing works

An Update on the Application of CRISPR Technology in Clinical Practice

Morshedzadeh, F., Ghanei, M., Lotfi, M., Ghasemi, M., Ahmadi, M., Najari-Hanjani, P., Sharif, S., Mozaffari‐Jovin, S., Peymani, M., & Abbaszadegan, M. R. (2023) · Molecular Biotechnology · doi:10.1007/s12033-023-00724-z · Cited by 60 · see citing works

Nanobiomaterial vectors for improving gene editing and gene therapy

Hu, S. W., Ding, T., Tang, H., Guo, H., Cui, W., & Shu, Y. (2023) · Materials Today · doi:10.1016/j.mattod.2023.04.011 · Cited by 58 · see citing works

Stimuli-responsive nanoformulations for CRISPR-Cas9 genome editing

Fang, T., Cao, X., Ibnat, M., & Chen, G. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01570-y · Cited by 61 · see citing works

Nanoparticles-mediated CRISPR-Cas9 gene therapy in inherited retinal diseases: applications, challenges, and emerging opportunities

Chien, Y., Hsiao, Y., Chou, S., Lin, T.-Y., Yarmishyn, A. A., Lai, W., Lee, M., Lin, Y., Lin, T.-W., Hwang, D., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01717-x · Cited by 58 · see citing works

Targeting Cancer with CRISPR/Cas9-Based Therapy

Balon, K., Sheriff, A., Jackow, J., & Łaczmański, Ł. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23010573 · Cited by 57 · see citing works

In vivo delivery of CRISPR-Cas9 genome editing components for therapeutic applications

Huang, K. L., Zapata, D. A., Tang, Y., Teng, Y., & Li, Y. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121876 · Cited by 55 · see citing works

A potential paradigm in CRISPR/Cas systems delivery: at the crossroad of microalgal gene editing and algal-mediated nanoparticles

Feng, S., Xie, X., Liu, J., Li, A., Wang, Q., Guo, D., Li, S., Li, Y., Wang, Z., Guo, T., et al. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02139-z · Cited by 58 · see citing works

Tissue-Specific Delivery of CRISPR Therapeutics: Strategies and Mechanisms of Non-Viral Vectors

Shalaby, K. E., Aouida, M., & El‐Agnaf, O. M. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197353 · Cited by 54 · see citing works

Latest Advances of Virology Research Using CRISPR/Cas9-Based Gene-Editing Technology and Its Application to Vaccine Development

Teng, M., Yao, Y., Nair, V., & Luo, J. (2021) · Viruses · doi:10.3390/v13050779 · Cited by 54 · see citing works

Responsive-DNA hydrogel based intelligent materials: Preparation and applications

Iqbal, S., Ahmed, F., & Xiong, H. (2021) · Chemical Engineering Journal · doi:10.1016/j.cej.2021.130384 · Cited by 52 · see citing works

Recent Advances in CRISPR/Cas9 Delivery Approaches for Therapeutic Gene Editing of Stem Cells

Lotfi, M., Rad, D. M., Mashhadi, S., Ashouri, A., Mojarrad, M., Mozaffari‐Jovin, S., Farrokhi, S., Hashemi, M., Lotfi, M., Warkiani, M. E., et al. (2023) · Stem Cell Reviews and Reports · doi:10.1007/s12015-023-10585-3 · Cited by 54 · see citing works

Nanoplatform‐Based In Vivo Gene Delivery Systems for Cancer Therapy

Luo, R., Le, H., Wu, Q., & Gong, C. (2024) · Small · doi:10.1002/smll.202312153 · Cited by 50 · see citing works

Recent Advances in Nanoenzymes Based Therapies for Glioblastoma: Overcoming Barriers and Enhancing Targeted Treatment

Wang, L., Gu, M., Zhang, X., Kong, T., Liao, J., Zhang, D., & Li, J. (2025) · Advanced Science · doi:10.1002/advs.202413367 · Cited by 47 · see citing works

Targeting of Uropathogenic Escherichia coli papG gene using CRISPR-dot nanocomplex reduced virulence of UPEC

Gupta, S., Kumar, P., Rathi, B., Verma, V., Dhanda, R. S., Devi, P., & Yadav, M. C. (2021) · Scientific Reports · doi:10.1038/s41598-021-97224-4 · Cited by 44 · see citing works

Application and perspective of CRISPR/Cas9 genome editing technology in human diseases modeling and gene therapy

Zhang, M., Li, H., & Jin, Y. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1364742 · Cited by 46 · see citing works

Emerging applications of gene editing technologies for the development of climate-resilient crops

Chavhan, R. L., Jaybhaye, S. G., Hinge, V. R., Deshmukh, A. S., Shaikh, U. S., Jadhav, P. K., Kadam, U. S., & Hong, J. C. (2025) · Frontiers in Genome Editing · doi:10.3389/fgeed.2025.1524767 · Cited by 43 · see citing works

CRISPR/Cas9-Mediated Genome Editing in Cancer Therapy

Ding, S., Liu, J., Han, X., & Tang, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216325 · Cited by 42 · see citing works

Engineered extracellular vesicles mediated CRISPR-induced deficiency of IQGAP1/FOXM1 reverses sorafenib resistance in HCC by suppressing cancer stem cells

He, C., Ali, D. J., Qi, Y., Li, Y., Sun, B., Liu, R., Sun, B., & Xiao, Z. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01902-6 · Cited by 41 · see citing works

Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review

Moradi, V., Khodabandehloo, E., Alidadi, M., Omidkhoda, A., & Ahmadbeigi, N. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1388475 · Cited by 42 · see citing works

Cytosine base editing inhibits hepatitis B virus replication and reduces HBsAg expression in vitro and in vivo

Smekalova, E. M., Martínez, M. G., Combe, E., Kumar, A., Dejene, S., Leboeuf, D., Chen, C., Dorkin, J. R., Shuang, L. S., Kieft, S., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.102112 · Cited by 41 · see citing works

CRISPR/Cas9 system: recent applications in immuno-oncology and cancer immunotherapy

Chen, C., Wang, Z., & Qin, Y. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00457-4 · Cited by 40 · see citing works

Recent progress in cancer vaccines and nanovaccines

Poudel, K., Vithiananthan, T., Kim, J. O., & Tsao, H. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122856 · Cited by 40 · see citing works

Cell and Gene Therapy for Anemia: Hematopoietic Stem Cells and Gene Editing

Anurogo, D., Budi, N. Y. P., Ngo, M.-H. T., Huang, Y., & Pawitan, J. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126275 · Cited by 37 · see citing works

CRISPR/Cas9-based application for cancer therapy: Challenges and solutions for non-viral delivery

Lin, Y., Feng, K.-K., Lu, J.-Y., Le, J., Li, W.-L., Zhang, B., Li, C., Song, X.-H., Tong, L.-W., & Shao, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.08.028 · Cited by 37 · see citing works

Nonviral In Vivo Delivery of CRISPR-Cas9 Using Protein-Agnostic, High-Loading Porous Silicon and Polymer Nanoparticles

Fletcher, R. B., Stokes, L. D., Kelly, I. B., Henderson, K. M., Vallecillo-Viejo, I. C., Colazo, J. M., Wong, B. V., Yu, F. Z., d’Arcy, R., Struthers, M. N., et al. (2023) · ACS Nano · doi:10.1021/acsnano.2c12261 · Cited by 35 · see citing works

Unlocking Genome Editing: Advances and Obstacles in CRISPR/Cas Delivery Technologies

Kaupbayeva, B., Tsoy, A., Safarova, Y., Nurmagambetova, A., Murata, H., Matyjaszewski, K. A., & Askarova, S. (2024) · Journal of Functional Biomaterials · doi:10.3390/jfb15110324 · Cited by 37 · see citing works

Strategies for High-Efficiency Mutation Using the CRISPR/Cas System

Feng, S., Wang, Z., Li, A., Xie, X., Liu, J., Li, S., Li, Y., Wang, B., Hu, L., Yang, L., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.803252 · Cited by 37 · see citing works

Non-viral nanocarriers for CRISPR-Cas9 gene editing system delivery

Tang, X., Wang, Z., Zhang, Y., Mu, W., & Han, X. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.135116 · Cited by 30 · see citing works

Nanotechnology‐based CRISPR/Cas9 delivery system for genome editing in cancer treatment

Zhou, S., Li, Y., Wu, Q., & Gong, C. (2024) · MedComm – Biomaterials and Applications · doi:10.1002/mba2.70 · Cited by 30 · see citing works

Recent Updates of the CRISPR/Cas9 Genome Editing System: Novel Approaches to Regulate Its Spatiotemporal Control by Genetic and Physicochemical Strategies

Allemailem, K. S., Almatroudi, A., Rahmani, A. H., Alrumaihi, F., Alradhi, A. E., Al-Subaiyel, A., Algahtani, M., Almousa, R. M., Mahzari, A., Sindi, A. A. A., et al. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s455574 · Cited by 33 · see citing works

Gene therapy in wound healing using nanotechnology

Pang, C., Fan, K. S., Wei, L., & Kolar, M. K. (2020) · Wound Repair and Regeneration · doi:10.1111/wrr.12881 · Cited by 28 · see citing works

Nanomaterial Strategies for Delivery of Therapeutic Cargoes

Ledesma, F., Ozcan, B., Sun, X., Medina, S. M., & Landry, M. P. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202107174 · Cited by 28 · see citing works

Nanotechnology prospects in brain therapeutics concerning gene-targeting and nose-to-brain administration

Wu, D., Salah, Y. A., Ngowi, E. E., Zhang, Y., Khattak, S., Khan, N. H., Wang, Y., Li, T., Guo, Z.-H., Wang, Y., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107321 · Cited by 28 · see citing works

Biosafety considerations triggered by genome-editing technologies

Li, X., Gao, Y., Zhang, Z., Deng, W., Cao, W., Wei, X. C., Gao, Z., Yao, L., Wang, S., Xie, Y., et al. (2025) · Biosafety and Health · doi:10.1016/j.bsheal.2025.05.003 · Cited by 27 · see citing works

Application of CRISPR‐Cas9 technology in diabetes research

Lotfi, M., Butler, A. E., Sukhorukov, V. N., & Sahebkar, A. (2023) · Diabetic Medicine · doi:10.1111/dme.15240 · Cited by 27 · see citing works

Nanostructures for prevention, diagnosis, and treatment of viral respiratory infections: from influenza virus to SARS-CoV-2 variants

Sharifi, E., Yousefiasl, S., Trovato, M., Sartorius, R., Esmaeili, Y., Goodarzi, H., Ghomi, M., Bigham, A., Moghaddam, F. D., Heidarifard, M., et al. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01938-8 · Cited by 29 · see citing works

Therapeutic applications of CRISPR /Cas9 gene editing technology for the treatment of ocular diseases

Sundaresan, Y., Yacoub, S., Kodati, B., Amankwa, C. E., Raola, A., & Zode, G. S. (2023) · FEBS Journal · doi:10.1111/febs.16771 · Cited by 25 · see citing works

CRISPR/Cas9 gene editing: a novel strategy for fighting drug resistance in respiratory disorders

Hussen, B. M., Najmadden, Z. B., Abdullah, S. R., Rasul, M. F., Mustafa, S. A., Ghafouri‐Fard, S., & Taheri, M. N. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01713-8 · Cited by 27 · see citing works

Current Knowledge on CRISPR Strategies Against Antimicrobial-Resistant Bacteria

Tagarro, C. D. L. F., Martín-González, D., Lucas, A. D., Bordel, S., & Santos‐Beneit, F. (2024) · Antibiotics · doi:10.3390/antibiotics13121141 · Cited by 23 · see citing works

Single AAV-mediated CRISPR-Nme2Cas9 efficiently reduces mutant hTTR expression in a transgenic mouse model of transthyretin amyloidosis

Wen, J., Cao, T., Wu, J., Chen, Y., Zhi, S., Huang, Y., Zhen, P., Wu, G., Aagaard, L., Zhong, J., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.05.010 · Cited by 23 · see citing works

Nanobiotechnology: traditional re-interpreting personalized medicine through targeted therapies and regenerative solutions

Chattopadhyay, S., Goswami, A., & Sil, M. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04038-6 · Cited by 23 · see citing works

Natural components as surface engineering agents for CRISPR delivery

Rabiee, N. (2023) · Environmental Research · doi:10.1016/j.envres.2023.116333 · Cited by 21 · see citing works

Synthetic Virus-Derived Nanosystems (SVNs) for Delivery and Precision Docking of Large Multifunctional DNA Circuitry in Mammalian Cells

Aulicino, F., Capin, J., & Berger, I. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12080759 · Cited by 21 · see citing works

Efficiency of Chitosan-Coated PLGA Nanocarriers for Cellular Delivery of siRNA and CRISPR/Cas9 Complex

Srivastav, A., Gupta, K., Chakraborty, D., Dandekar, P. P., & Jain, R. D. (2020) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-020-09496-4 · Cited by 21 · see citing works

Versatile modification of the CRISPR/Cas9 ribonucleoprotein system to facilitate in vivo application

Sun, B., Chen, H., & Gao, X. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.08.007 · Cited by 20 · see citing works

Knock-In of a Large Reporter Gene via the High-Throughput Microinjection of the CRISPR/Cas9 System

Chen, S., Jiao, Y., Pan, F., Guan, Z., Cheng, S. H., & Sun, D. B. (2022) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2022.3149530 · Cited by 20 · see citing works

Reversal of hepatic fibrosis by the co-delivery of drug and ribonucleoprotein-based genome editor

Gu, J., Sun, J., Tian, K. V., Bian, J., Peng, J., Xu, S. Q., & Zhao, L. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122133 · Cited by 19 · see citing works

Overcoming therapy resistance in pancreatic cancer: challenges and emerging strategies

du Toit‐Thompson, T., Leck, L. Y. W., Gillson, J., Pavlakis, N., Gill, A. J., Samra, J. S., Mittal, A., & Sahni, S. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115647 · Cited by 19 · see citing works

Optimization of CRISPR–Cas system for clinical cancer therapy

Meng, X. L., Wu, T., Lou, Q., Niu, K., Jiang, L., Xiao, Q., Xu, T., & Zhang, L. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10474 · Cited by 18 · see citing works

Types of RNA therapeutics

Goleij, P., Babamohamadi, M., Rezaee, A., Sanaye, P. M., Tabari, M. A. K., Sadreddini, S., Arefnezhad, R., & Motedayyen, H. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.12.022 · Cited by 19 · see citing works

Unravelling fungal genome editing revolution: pathological and biotechnological application aspects

Hassane, A. M. A., Obiedallah, M., Karimi, J., Khattab, S. M. R., Hussein, H. R., Abo-Dahab, Y., Eltoukhy, A., Abo-Dahab, N. F., & Abouelela, M. E. (2025) · Archives of Microbiology · doi:10.1007/s00203-025-04360-w · Cited by 17 · see citing works

Biosafety materials: Ushering in a new era of infectious disease diagnosis and treatment with the CRISPR/Cas system

Zhang, Y., Li, Z., Essola, J. M., Ge, K., Dai, X., He, H., Xiao, H., Weng, Y., & Huang, Y. (2022) · Biosafety and Health · doi:10.1016/j.bsheal.2022.03.010 · Cited by 17 · see citing works

State-of-art high-performance Nano-systems for mutated coronavirus infection management: From Lab to Clinic

Bhattacharjee, R., Dubey, A. K., Ganguly, A., Bhattacharya, B., Mishra, Y. K., Mostafavi, E., & Kaushik, A. K. (2022) · OpenNano · doi:10.1016/j.onano.2022.100078 · Cited by 17 · see citing works

Carbon-based nanomaterials for CRISPR/Cas delivery: a perspective on the design approach

Safarkhani, M., Saeb, M. R., Lee, J., Huh, Y. S., & Rabiee, N. (2023) · Carbon letters · doi:10.1007/s42823-023-00655-4 · Cited by 17 · see citing works

Nanotechnological approaches for the targeted delivery of CRISPR-Cas systems for genomic modifications, biomolecular sensing, and precision medicine

Baig, M. M. F. A., Chien, W. T., & Chair, S. Y. (2025) · Biomaterials Science · doi:10.1039/d5bm00711a · Cited by 19 · see citing works

Methods for CRISPR-Cas as Ribonucleoprotein Complex Delivery In Vivo

Bykonya, A. G., Лавров, А. В., & Smirnikhina, S. (2022) · Molecular Biotechnology · doi:10.1007/s12033-022-00479-z · Cited by 16 · see citing works

The Promise of Emergent Nanobiotechnologies for In Vivo Applications and Implications for Safety and Security

Arnold, A. M., Bradley, A. M., Taylor, K., Kennedy, Z. C., & Omberg, K. M. (2022) · Health Security · doi:10.1089/hs.2022.0014 · Cited by 16 · see citing works

CRISPR/Cas9 as a Mutagenic Factor

Shumega, A. R., Pavlov, Y. I., Chirinskaite, A. V., Rubel, A. A., Inge-Vechtomov, S. G., & Stepchenkova, E. I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020823 · Cited by 18 · see citing works

Emerging Gene-editing nano-therapeutics for Cancer

Nujoom, N., Koyakutty, M., Biswas, L., Rajkumar, T., & Nair, S. V. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e39323 · Cited by 16 · see citing works

Application and Prospect of CRISPR/Cas9 Technology in Reversing Drug Resistance of Non-Small Cell Lung Cancer

Huang, L., Liao, Z., Liu, Z., Chen, Y., Huang, T., & Xiao, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.900825 · Cited by 16 · see citing works

Gene network analysis of oxaliplatin-resistant colorectal cancer to target a crucial gene using chitosan/hyaluronic acid/protamine polyplexes containing CRISPR-Cas9

Shirani-Bidabadi, S., Mirian, M., Varshosaz, J., Tavazohi, N., Hamid, M., & Shariati, L. (2023) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2023.130385 · Cited by 15 · see citing works

CRISPR/Cas9-mediated knock-in of BRCA1/2 mutations restores response to olaparib in pancreatic cancer cell lines

Witz, A., Dardare, J., François, A., Husson, M., Rouyer, M., Demange, J., Merlin, J., Gilson, P., & Harlé, A. (2023) · Scientific Reports · doi:10.1038/s41598-023-45964-w · Cited by 16 · see citing works

Unlocking the potential of RNA-based therapeutics in the lung: current status and future directions

Man, H. S. J., Moosa, V. A., Singh, A. N., Wu, L., Granton, J. T., Juvet, S., Hoang, C. D., & de Perrot, M. E. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1281538 · Cited by 14 · see citing works

Topical gene editing therapeutics using lipid nanoparticles: ‘gene creams’ for genetic skin diseases?

Guri, I., Alrokh, Y., Kim, Y., Maeshima, R., Graham, C., Hart, S. L., McGrath, J. A., & Jackow, J. (2023) · British Journal of Dermatology · doi:10.1093/bjd/ljad528 · Cited by 18 · see citing works

Role of CRISPR/Cas9 in the treatment of Duchenne muscular dystrophy and its delivery strategies

Agrawal, P., Harish, V., Mohd, S., Singh, S. K., Tewari, D., Tatiparthi, R., Harshita, Vishwas, S., Sutrapu, S., Dua, K., et al. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122003 · Cited by 14 · see citing works

Advances in Nanoparticles as Non-Viral Vectors for Efficient Delivery of CRISPR/Cas9

Kim, M., Hwang, Y., Lim, S., Jang, H., & Kim, H. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16091197 · Cited by 75 · see citing works

Challenges in delivery systems for CRISPR-based genome editing and opportunities of nanomedicine

Sioson, V. A., Kim, M., & Joo, J. (2021) · Biomedical Engineering Letters · doi:10.1007/s13534-021-00199-4 · Cited by 115 · see citing works

Nanotechnology based CRISPR/Cas9 system delivery for genome editing: Progress and prospect

Deng, H., Huang, W., & Zhang, Z. (2019) · Nano Research · doi:10.1007/s12274-019-2465-x · Cited by 69 · see citing works

NANOTECHNOLOGY-ENABLED NON-VIRAL DELIVERY SYSTEMS FOR CRISPR/CAS9 GENE THERAPY: CURRENT PROGRESS AND TRANSLATIONAL CHALLENGES

B. Yaswanth Vinayak1, D. N. (2026) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.23374392

Nanoparticles-mediated CRISPR/Cas9 delivery: Recent advances in cancer treatment

Aghamiri, S., Talaei, S., Ghavidel, A. A., Zandsalimi, F., Masoumi, S., Hafshejani, N. H., & Jajarmi, V. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.101533 · Cited by 69 · see citing works